Tenax Therapeutics appoints Robyn Hunter to Board, cures Nasdaq audit committee compliance

TENAX THERAPEUTICS, INC.

Robyn Hunter appointed as independent director and chair of Audit and Compliance Committee, effective Jan 28, 2022.
Hunter is CFO of Fortress Biotech; adds financial and life sciences expertise to the Board.
Appointment resolves non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) for audit committee composition.
Board remains majority independent following her appointment.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robyn M. Hunter

Member of the Board

TENX · TENAX THERAPEUTICS, INC.

Effective: 2022-01-28
Filed: January 31, 2022, 6:59 PM ET

On January 26, 2022, the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. (the “Company”) appointed Robyn M. Hunter as a member of the Board, effective January 28, 2022, to serve until the Company’s 2022 annual meeting of stockholders or until her successor is duly elected and qualified.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robyn M. Hunter was appointed as Member of the Board at TENAX THERAPEUTICS, INC..

Action: appointed
Role: Member of the Board

Exact text from the filing

On January 26, 2022, the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. (the “Company”) appointed Robyn M. Hunter as a member of the Board, effective January 28, 2022, to serve until the Company’s 2022 annual meeting of stockholders or until her successor is duly elected and qualified.

View on SEC.gov

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001568276-22-000302

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.